Experimental infection of the pig with Mycobacterium ulcerans : a novel model for studying the pathogenesis of Buruli ulcer disease by Bolz, Miriam et al.
Experimental Infection of the Pig with Mycobacterium
ulcerans: A Novel Model for Studying the Pathogenesis
of Buruli Ulcer Disease
Miriam Bolz1,2, Nicolas Ruggli3, Marie-The´re`se Ruf1,2, Meret E. Ricklin3, Gert Zimmer3, Gerd Pluschke1,2*
1 Swiss Tropical and Public Health Institute, Basel, Switzerland, 2University of Basel, Basel, Switzerland, 3 Institute of Virology and Immunology (IVI), Mittelha¨usern,
Switzerland
Abstract
Background: Buruli ulcer (BU) is a slowly progressing, necrotising disease of the skin caused by infection with
Mycobacterium ulcerans. Non-ulcerative manifestations are nodules, plaques and oedema, which may progress to ulceration
of large parts of the skin. Histopathologically, BU is characterized by coagulative necrosis, fat cell ghosts, epidermal
hyperplasia, clusters of extracellular acid fast bacilli (AFB) in the subcutaneous tissue and lack of major inflammatory
infiltration. The mode of transmission of BU is not clear and there is only limited information on the early pathogenesis of
the disease available.
Methodology/Principal Findings: For evaluating the potential of the pig as experimental infection model for BU, we
infected pigs subcutaneously with different doses of M. ulcerans. The infected skin sites were excised 2.5 or 6.5 weeks after
infection and processed for histopathological analysis. With doses of 26107 and 26106 colony forming units (CFU) we
observed the development of nodular lesions that subsequently progressed to ulcerative or plaque-like lesions. At lower
inoculation doses signs of infection found after 2.5 weeks had spontaneously resolved at 6.5 weeks. The observed
macroscopic and histopathological changes closely resembled those found in M. ulcerans disease in humans.
Conclusion/Significance: Our results demonstrate that the pig can be infected with M. ulcerans. Productive infection leads
to the development of lesions that closely resemble human BU lesions. The pig infection model therefore has great
potential for studying the early pathogenesis of BU and for the development of new therapeutic and prophylactic
interventions.
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Introduction
Buruli ulcer (BU), caused by infection with Mycobacterium ulcerans,
is a human disease of the skin primarily affecting subcutaneous fat
tissue and leading to ulceration of the overlying dermal and
epidermal layers [1,2]. The disease is reported from countries
worldwide but has its highest prevalence in West Africa [3].
Natural reservoirs of M. ulcerans as well as the mode(s) of
transmission are not clearly identified [3,4]. While for a long time
wide surgical excision was the only treatment option for BU, since
2004 the World Health Organization (WHO) recommends
antibiotic therapy with rifampicin and streptomycin for 8 weeks
[5]. This change in standard treatment has reduced recurrence
rates to less than 2% [6–9].
M. ulcerans produces the polyketide exotoxin mycolactone that is
responsible for the necrotizing nature of BU [10]. Three distinct
non-ulcerative stages of the disease are described: subcutaneous,
painless and movable nodules or papules, oedema and plaques. All
three stages may progress to ulceration once the destruction of the
subcutis results in collapse of the overlying epidermis and dermis
[11].
Ulcerative BU lesions have been histopathologically well described
through the analysis of excised tissue from surgically treated patients.
Coagulative necrosis, fat cell ghosts and epidermal hyperplasia
together with the presence of extracellular clusters of acid fast bacilli
(AFB) in the absence of major inflammatory infiltrates in central parts
of the lesions are considered hallmarks of the disease and can also be
used for histopathological diagnosis [12,13]. However, early, pre-
ulcerative stages have been described less frequently, because in
particular in the African BU endemic regions patients are rarely
reporting at treatment centres during early stages of the disease.
Furthermore, with the replacement of surgical treatment by
chemotherapy, tissue samples are not easily available any longer.
Therefore, a suitable experimental animal infection model is required
to contribute to the understanding of early host-pathogen interactions
and pathogenesis in BU.
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A range of animal species have been reported of being naturally
infected with M. ulcerans and of developing ulcerative lesions.
These include koalas, possums, cats, dogs and horses [14–21].
Except for possums which appear to be unusually susceptible to
the disease, these animal infections seem to occur only sporadically
[22]. Experimental M. ulcerans infections have been performed
with amphibians, armadillos, rats, mice, guinea pigs and monkeys,
with a mouse foot pad model being most widely used for studying
the efficacy of prophylactic and therapeutic interventions [23–29].
Here we propose the pig (Sus scrofa) as experimental M. ulcerans
infection model, since pigs are closely related to humans in terms
of many aspects of anatomy and physiology [30,31]. The pig is
widely used as a model in dermatological studies because pig skin,
in contrast to rodent skin, has striking similarities to human skin
[32]. Not only the thickness of the epidermis and the dermis are
comparable to human skin [33], but also the presence of a
subcutaneous fat cell layer is favouring the pig model over the
mouse foot pad model commonly used for analysing BU
pathogenesis. Furthermore, the porcine immune system reflects
the human immune system in many aspects better than the murine
immune system does [34,35]. For all these reasons we explored
here the potential of the pig to serve as model for human M.
ulcerans infection.
Materials and Methods
Ethical statement
All animal experiments described here were approved by the
Animal Welfare Committee of the Canton of Berne under licence
number BE50/11, and conducted in compliance with the Swiss
animal protection law and with other national and international
guidelines.
Bacteria
The M. ulcerans strain used in this study was isolated in 2010
from a swab taken from the undermined edges of the ulcerative
lesion of a Cameroonian BU patient [4]. Five passages of the
strain after isolation were done in Bac/T medium (Biomerieux) at
30uC. For preparation of the inoculum, bacteria were cultivated
in Bac/T medium for 6 weeks, recovered by centrifugation and
diluted in sterile phosphate-buffered saline (PBS) to 375 mg/ml
wet weight corresponding to 26108 CFU/ml as determined by
plating serial dilutions on 7H9 agar plates. From this stock
solution suspension serial dilutions in PBS were prepared for
infection.
Author Summary
Buruli ulcer caused by Mycobacterium ulcerans infection is
a necrotizing disease of the skin and the underlying
subcutaneous tissue. Since the skin of pigs (Sus scrofa) has
striking structural and physiological similarities with
human skin, we investigated whether it is possible to
develop an experimental M. ulcerans infection model by
subcutaneous injection of the mycobacteria into pig skin.
Injection of 26106 or 26107 colony forming units of M.
ulcerans led to the development of lesions that were both
macroscopically and microscopically very similar to human
Buruli ulcer lesions. In particular for the characterization of
the pathogenesis of Buruli ulcer and of immune defence
mechanisms against M. ulcerans, the pig model appears to
be superior to the mouse foot pad model commonly used
for the evaluation of the efficacy of chemotherapeutic
regimens.
Figure 1. Macroscopic appearance of pig skin infected with M. ulcerans. Development of representative lesions 2.5 weeks or 6.5 weeks after
subcutaneous infection with 26107 (B1, D1 and E1) or 26106 (C1) CFU is depicted and compared to a site left uninfected (A1). Excised tissue
specimens were fixed and vertically cut in half to visualize macroscopically visible alteration in tissue structure (A2–E2). For high inoculation doses ($
26106 CFU) the formation of nodules (B1) with necrotic centres was observed already 2.5 weeks after infection (B2). These yellow centres indicative
for coagulative necrosis were surrounded by a reddish ring (B2). At 6.5 weeks after infection, these nodules had progressed into a small ulcer or a
plaque (D1, E1) associated with marked macroscopically visible alterations in tissue structure (D2, E2). At sites injected with 26106 CFU nodules with
greyish discoloration of the dermis had developed 6.5 weeks after injection of M. ulcerans (C1, C2).
doi:10.1371/journal.pntd.0002968.g001
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Infection and inoculation with synthetic mycolactone
A/B
Specific pathogen-free 2-month-old pigs (Large White) from
the in-house breeding unit of the Institute of Virology and
Immunology (IVI) were kept under BSL3 conditions one week
prior and during the time of experimental infection. Animals
were checked once daily for macroscopic signs of infection, had
ad libitum access to water and were fed daily with complete
pelleted food.
Pigs were infected on both flanks at four to six infection sites
with 100 ml of M. ulcerans suspension, containing 26107,
26106, 26105, 26104 or 26103 CFU. Injection areas were
wiped with 70% ethanol and bacterial suspensions injected
subcutaneously with a 26G needle. Individual infection sites
were encircled with a black marker and the labelling renewed
at least once a week. Animals were euthanized at 2.5 weeks or
6.5 weeks post-infection and tissue samples taken as described
below.
In addition, the effect of mycolactone was studied directly by
injecting 5 mg or 0.5 mg of synthetic mycolactone A/B [36] and
analysing tissue specimens taken 2.5 weeks later.
Euthanasia and necropsy
Pigs were euthanized by intravenous injection of pentobarbital
(150 mg/kg bodyweight) and subsequent exsanguination. Skin
tissue at infection sites was extensively excised with a scalpel and
scissors, including all layers of the skin down to the fascia, and
samples were immediately transferred to 10% neutral-buffered
Formalin solution (approx. 4% formaldehyde).
Histopathological analysis
After fixation samples were transferred to 70% ethanol for
storage and transport, dehydrated and embedded into paraffin.
5 mm thin sections were cut, deparaffinised, rehydrated and
directly stained with Haematoxylin/Eosin (HE) or Ziehl-Neelsen/
Methylene blue (ZN) according to WHO standard protocols [11].
Stained sections were mounted with Eukitt mounting medium
(Fluka). Pictures were taken with a Leica DM2500B microscope or
with an Aperio scanner.
Results
Macroscopic appearance of Mycobacterium ulcerans
infected pig skin
In order to assess early effects of the subcutaneous experimental
infection of pigs with doses of 26103 to 26107 M. ulcerans CFU,
injection sites were closely monitored for macroscopic changes of
the skin. At 2.5 weeks after injection of the bacteria, first changes
in colouration and thickness of the skin became apparent at the
sites inoculated with the highest inoculation doses, 26107 and
26106 CFU (Fig. 1, B1). Like nodular BU lesions in humans, these
early lesions were elevated, movable, firm and palpable. When
these skin areas were excised 2.5 weeks and 6.5 weeks after
infection and vertically cut in half after fixation in formalin,
roundish yellow structures reflecting coagulative necrosis in the
dermis became macroscopically apparent (Fig. 1, B2). A belt with
reddish colour, reflecting infiltrating cells and bleeding into the
skin, was observed around the necrotic core. While these
structures were larger at sites inoculated with a dose of
26107 CFU than at sites inoculated with 26106 CFU, the general
architecture observed with both inoculation doses was similar. At
sites inoculated with ,26105 CFU, no macroscopically visible
alterations of the skin were found 2.5 weeks after infection (Fig. 1,
A1 and A2).
At 6.5 weeks after experimental infection, sites injected with
the highest inoculation dose had either enlarged to an indurated
plaque (Fig. 1 E1) or ulcerated (Fig. 1, D1). At sites injected with
26106 CFU, nodular lesions were observed that were flatter and
less palpable compared to those detected 2.5 weeks after infection
(Fig. 1, C1). These lesions were macroscopically clearly visible in
cross sections through the tissue (Fig. 1, C2). Nodular and
ulcerative lesions exhibited greyish/reddish colour changes in the
dermis and subcutis (Fig. 1, C2 and D2). The plaque lesion
developing after injection with 26107 CFU appeared as long
cord-like structure with a centre made of yellowish necrotic
slough, surrounded by several layers differing in colouration
(Fig. 1, E2).
Histopathological features of the pig skin 2.5 weeks after
experimental infection
Microcopically, infiltrating immune cells were found 2.5 weeks
after infection at all sites inoculated with $26104 CFU (Fig. 2,
A1, B1, C1 and D1). As expected from the macroscopically
observed signs, the most pronounced histopathological alterations
were associated with the two highest inoculation doses (26107 and
26106 CFU). The non-ulcerative lesions that developed between
the dermis and the underlying muscle tissue displaced the fat layer
(Fig. 2, A1 and B1) and caused the macroscopically visible
elevation of the skin (Fig. 1, B1). Microscopically, a necrotic core
surrounded by large numbers of infiltrating cells and interspersed
with fat cell ghosts was observed (Fig. 2, A2 and B2).
At sites infected with 26105 CFU, no necrotic core structures
but some fat cell ghosts and accumulations of infiltrating cells were
found (Fig. 2, C1 and C2). The infection with 26104 CFU caused
a small accumulation of infiltrating cells (Fig. 2, D1 and D2) and
no signs of infection and/or inflammation were observed at sites
inoculated with the lowest dose (26103 CFU).
Histopathological features of the pig skin 6.5 weeks after
experimental infection
At 6.5 weeks after experimental infection, histopathological
changes were only found at sites that had been injected with
26107 or 26106 CFU. In contrast, the skin appeared macro- and
microscopically healthy following infection with lower doses of M.
ulcerans, exhibiting intact epidermis and fat cells, undistorted
collagen fibre networks and no marked inflammatory infiltration
(Fig. 3, D1 and D2).
Where the infection focus had started to ulcerate, strong
infiltration towards the destroyed epidermis was observed (Fig. 3,
A1 and A2). No AFB were found in this region, indicative for loss
of the necrotic core with the major burden of AFB through the
ulceration (Fig. 3, A2, Fig. 4, B1 and B2). Small clusters of AFB
Figure 2. Microscopic appearance of pig skin 2.5 weeks after experimental infection. Histologic sections stained with HE. Infiltrating cells
were found in the fat layer between dermis and muscle tissue at sites infected with $26104 CFU (A1, B1, C1 and D1). While the two highest
inoculation doses led to the development of lesions with a necrotic core surrounded by strong infiltration (A2, B2), infiltration but no necrotic core
was observed when doses of 26104 and 26103 CFU were used (C2, D2 insert). Fat cell ghosts were found at sites infected with the three highest
inoculation doses (A2, B2 and C2). x: necrosis, y: infiltration, z: fat cell ghosts.
doi:10.1371/journal.pntd.0002968.g002
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were found at deeper sites in the tissue, lateral to the ulceration site
(Fig. 4, B3–B5). Infiltration and destruction of collagen fibres
extended into the lower part of the dermis and the upper part of
the subcutis, reaching far beyond the area where the epidermis
was destroyed (Fig. 3, A1), indicating the formation of undermined
edges (Fig. 3, A2, dotted line).
The overall architecture of the plaque lesion that had developed
resembled the nodular stages seen 2.5 weeks after infection, i.e. a
necrotic centre was surrounded by layers of infiltrating cells (Fig. 3,
B1). While large clumps of extracellular AFB were found in the
necrotic core after injection of 26107 CFU (Fig. 3, B2), AFB were
less abundant and bacterial clumps smaller when 26106 CFU
were used for infection (Fig. 3, C2). Fig. 4A depicts the complex
architecture of a plaque lesion (26107 CFU dose) with several
distinct belts of infiltrating cells surrounding a central necrotic core
which contained huge clusters of AFB but was completely devoid
of infiltration (Fig. 4A, Ring 1, A1 and A2). In the surrounding
ring 2, AFB were scarce and had mostly a beaded appearance. In
addition to these single AFB, small globi-like clusters of AFB were
found, along with Methylene blue stained remains of infiltrating
cells (Fig. 4A, Ring 2, A3 and A4). Ring 3 contained mostly small
infiltrating cells that appeared intact, and some acid-fast bacterial
debris (Fig. 4A, Ring 3, A5 and A6). The outermost layer that
could be distinguished did not contain AFB and was mainly built
by macrophages and lymphocytes (Fig. 4A, Ring 4, A7). Hence,
the number and integrity of AFB decreased from the centre to the
periphery of the lesion, whereas the integrity of the cellular
infiltration showed an opposite trend, most likely reflecting levels
of the cytotoxic macrolide mycolactone decreasing from centre to
periphery.
Histopathological resemblance of pig and human BU
lesions
All key features of BU pathology in humans were also found in
the experimentally infected pig skin. Already 2.5 weeks after
infection, coagulative necrosis (Fig. 5, A1), fat cell ghosts (Fig. 5,
A2) and extracellular clusters of AFB (Fig. 5, A3 and A4) were
detected. Slight epidermal hyperplasia was already observed at 2.5
weeks and became more pronounced 6.5 weeks after infection
(Fig. 5, A5–A7). At this time, typical histopathological hallmarks of
more advanced human BU lesions also emerged in the infected pig
skin, namely formation of granulomas (Fig. 5, A8) and presence of
giant cells (Fig. 5, A9). Not only experimental infection with M.
ulcerans led to these typical alterations in the skin, but also the
injection of synthetic mycolactone A/B (Fig. 5B).
Development of satellite infection foci
Besides the general histopathological changes, another similarity
to findings in human BU [37] was observed: the formation of
satellite infection foci adjacent to the primary lesion. A striking
example for this is depicted in Fig. 4B where two satellite foci with
small clusters of AFB in a necrotic core were found peripheral to
the ulcerated main infection focus (Fig. 4B, Region 2). Likewise in
the plaque lesion depicted in Fig. 4A, clusters of AFB were found
near the main infection focus (Fig. 4A, Ring 5, A8).
Discussion
Detailed studies on the early pathogenesis of BU in an animal
model closely mimicking human BU would be very important for
a better understanding of host-pathogen interactions and the
relative importance of different effector functions of the innate and
adaptive immune system against M. ulcerans. Here we explored the
potential of the pig to serve as model for human M. ulcerans
infection. After having infected pigs subcutaneously with high
doses (26106 or 26107 CFU) of M. ulcerans bacteria, we observed
the development of different forms of BU lesions (nodules, plaques
and ulcers). Macroscopic and histopathological changes closely
mirrored human BU. Challenge with lower doses (26103 to
26105 CFU) resulted in limited tissue destruction and/or infiltra-
tion 2.5 weeks after infection, which resolved spontaneously until
week 6.5. Likewise, the dose of bacteria transmitted may be of
critical importance for the outcome of a natural M. ulcerans
infection in humans. Sero-epidemiological analyses in human
populations living in BU endemic areas have indicated that
exposure to M. ulcerans often leads to self-resolving, non-
symptomatic infections, as indicated by development of M. ulcerans
specific antibody responses [38,39]. While macrophages and other
immune cells might be able to eliminate smaller numbers of
scattered M. ulcerans cells, microcolonies of a critical size may
develop a protective cloud of mycolactone around them. If the
local concentration of the macrolide cytotoxin exceeds a certain
level, infiltrating cells may be killed before they can reach the
bacteria. This leads to the characteristic picture of clusters of
extracellular AFB located primarily in the necrotic core of
advanced lesions, which is devoid of living infiltrating immune
cells, but contains debris of early inflammatory infiltrates [40,41].
In our study, we observed round elevations of the skin already
2.5 weeks after infection. These alterations were firm, movable
and clearly palpable and hence displayed the characteristic
features of human BU nodules [11]. Microscopic investigation of
the infected skin sites revealed that most histopathological
hallmarks of BU had already developed during the first 2.5 weeks
of infection if 26106 or 26107 CFU of M. ulcerans was used. The
experimentally induced nodules exhibited a necrotic core
containing extracellular AFB surrounded by infiltrating cells and
fat cell ghosts. Subcutaneous injection of the bacteria led to the
formation of an infection focus in the lower dermis and subcutis,
where it is also typically found in human BU [13].
In ulcerative human BU lesions AFB are typically focally
distributed and not evenly dispersed in the affected tissue [37,42].
Ulceration leads to the shedding of necrotic tissue containing
masses of AFB. Therefore the bacterial burden is usually higher in
non-ulcerative lesions than in ulcers, where the majority of the
remaining AFB reside in the undermined edges of the ulcers. Our
histopathological analyses showed, that like in human BU disease
[37], satellite lesions may develop near the primary lesion. These
may emerge from globi-like accumulations of AFB originating
from bacteria that were internalized and transported to distant
sites by phagocytic cells. Globi-like accumulations are also found
in human BU [43] and in experimentally infected mice [44–46].
Again, these microcolonies may have to reach a critical size to be
Figure 3. Microscopic appearance of pig skin 6.5 weeks after experimental infection. Histologic sections stained with Haematoxylin/Eosin
(HE) (A1, A2, B1, C1, D1 and D2) or Ziehl-Neelsen/Methylene blue (ZN) (B2, C2). At sites injected with 26107 CFU nodules had either developed into a
small ulcer with destroyed epidermis (z), strong infiltration and indications for the development of undermined edges (A1, A2, dotted line) or into a
plaque with a necrotic core surrounded by infiltrating cells (B1). x: intact epidermis, y: epidermal hyperplasia, z: destroyed/missing epidermis. The site
infected with 26106 CFU showed a similar architecture as the plaque but flatter, less organized and with a smaller overall circumference (C1). Both
lesions comprised AFB in their necrotic cores, either in big clumps (B2) or in smaller numbers and smaller aggregations (C2). No signs of infection,
inflammation and pathology were observed at sites inoculated with 26105 CFU (D1, D2) or less (not shown).
doi:10.1371/journal.pntd.0002968.g003
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able to develop a protective cloud of mycolactone around them.
The emergence of only small numbers of newly established
microcolonies may explain why borders of advanced ulcers often
appear to be very heterogeneous with respect to disease activity
with some regions displaying progressive tissue destruction and
others showing spontaneous healing tendencies.
At 6.5 weeks after infection with 26106 or 26107 CFU of M.
ulcerans, lesions that were still closed comprised a necrotic centre
containing clumps of AFB surrounded by well stratified belts of
infiltrating cells. Similarly, lesions consisting of a necrotic core
surrounded by an inner belt of CD14 positive monocytes/
macrophages and a more external belt of CD3 positive T-cells
have been described in human BU [47]. The integrity and number
of bacteria was decreasing to the outer rim of the lesion. In
contrast, the density and integrity of the cellular infiltrates
decreased towards the necrotic core.
Figure 4. Containment of large amounts of AFB in the necrotic core and development of satellite microcolonies. Histologic sections
stained with ZN. A plaque (A) and a small ulcer (B) are shown that developed 6.5 weeks after infection with 26107 CFU. The ulcerated lesion was
strongly infiltrated at the site of ulceration, where no AFB were found (Region 1, B1, B2). Lateral and between dermis and muscle tissue infiltrating
cells enclosed small necrotic areas (Region 2, B3), where AFB were found as satellite microcolonies (B4, B5). The plaque consisted of distinct layers of
infiltrating cells encasing a necrotic core containing large clumps of bacteria (Ring 1, A1, A2). A second and third ring with decreasing bacterial load
and integrity and increasing integrity of infiltrating cells were layered around this core (Ring 2, A3, A4 and Ring 3, A5, A6). A belt of intact cells was
surrounding these three inner layers. It did not contain any AFB (Ring 4, A7) except for a microcolony peripheral to the main bacterial burden (Ring 5,
A8).
doi:10.1371/journal.pntd.0002968.g004
Figure 5. Histophathological hallmarks of Buruli ulcer in experimentally infected pig skin. Histologic sections stained with Haematoxylin/
Eosin (HE) (A1, A2, A5, A6, A7, A8, A9, B1, B2 and B3) or Ziehl-Neelsen/Methylene blue (ZN) (A3, A4). A: All typical histopathological features of BU in
humans were found in infected pig skin. A1: necrosis, A2: fat cell ghosts, A3 and A4: extracellular clusters of AFB, A5: healthy epidermis, A6: moderate
epidermal hyperplasia, A7: strong epidermal hyperplasia, A8: granuloma formation, A9: giant cells. B: Histopathological changes induced by
mycolactone injection. B1: necrosis, B2: fat cell ghosts, B3: giant cells.
doi:10.1371/journal.pntd.0002968.g005
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In the pig model first macroscopic signs of infection (nodules)
developed relatively fast after injection of a high number of
bacteria. For human BU disease in Uganda and Southern
Australia incubation periods of 4–13 weeks and 5–38 weeks have
been estimated, respectively [48]. However, incubation periods as
short as 2–3 weeks have also been described [49]. Despite
extensive analyses we did not find bacteria in the tissue with low
inoculation doses at the 6.5 week time point. Therefore we assume
that also at later time points lesions would not develop with these
low infection doses. It is possible that pigs are more resistant to M.
ulcerans infection than humans. Consequently, the size of the
inoculum to achieve productive experimental infection may be
higher for pigs than for the natural infection of humans. This high
experimental inoculation dose may have led to fast progression of
the disease.
In conclusion, our findings indicate that the pig is a very good
animal model to study many aspects of M. ulcerans infection. Pig
skin represents a much closer model for human skin than murine
foot pads, ears or tails with respect to physiology, structure and
abundance of fat tissue [50]. In addition, the immune system of the
pig resembles the human system more closely than that of the
mouse [34]. In particular the development of new therapeutic and
prophylactic interventions might benefit from the porcine M.
ulcerans infection model.
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